EGFR-IN-44

Name: EGFR-IN-44
Brand: MedChemExpress
SKU: HY-145844

Cat. No.: HY-145844: FAQs
Data Sheet Handling Instructions

Molarity Calculator

EGFR-IN-44 (Compound 6a) is a potent, orally active EGFR tyrosine kinase inhibitor with an IC₅₀ of 4.11 nM. EGFR-IN-44 induces cell apoptosis and shows an oral bioavailability value of 33.57%. EGFR-IN-44 can be studied for non-small-cell lung cancers.

For research use only. We do not sell to patients.

EGFR-IN-44 Chemical Structure

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All EGFR Isoform Specific Products:

View All Isoforms

EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

IC₅₀: 0.26 nM (EGFR T790M/L858R), 1.33 nM (EGFR L858R), 4.11 nM (EGFR)^[1]

In Vitro

EGFR-IN-44 (Compound 6a) (0-10 µM, 72 h) shows anti-proliferative activities against tumor cell lines^[1].
EGFR-IN-44 binds to the ATP binding site of EGFR^[1].
EGFR-IN-44 (0-10 nM, 48 h) induces H1975 cell apoptosis via the mitochondrial pathway, arrests cell cycle in G0/G1 phase, and suppresses cell migration^[1].
EGFR-IN-44 (0-10 nM, 48 and 72h) shows hypotoxicity against normal cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	H1975 (EGFR^T790M/L858R), PC9 (EGFR^del19), and H292 (EGFR^WT)
Concentration:	0-10 µM
Incubation Time:	72 h
Result:	Showed anti-proliferative activities with IC₅₀ values of 0.0022 ± 0.001, 0.0048 ± 0.001, and 4.499 ± 0.057 µM against H1975, PC9, and H292 cells, respectively.

Apoptosis Analysis^[1]

Cell Line:	H1975
Concentration:	1, 5, and 10 nM
Incubation Time:	48 h
Result:	Effectively induced cell apoptosis in a dose-dependent manner. Resulted in 33.7%, 52.4%, and 56.2% apoptosis at 1, 5, and 10 µM, respectively, compared to 5.81% apoptosis in the control group.

Western Blot Analysis^[1]

Cell Line:	H1975
Concentration:	5, 10, and 25 nM
Incubation Time:	48 h and 72 h
Result:	Dose-dependently upregulated the expression levels of the proapoptotic proteins Bad and Bax and downregulated the expression level of the antiapoptotic protein Bcl-2. Sufficiently reduced the phosphorylation of EGFR and AKT.

Cell Cycle Analysis^[1]

Cell Line:	H1975
Concentration:	5 nM
Incubation Time:	0, 12, 24, or 48 h
Result:	Exhibited a significant increase in the G0/G1 cell population and a dramatic decrease in G2/M phase.

Cell Cytotoxicity Assay^[1]

Cell Line:	LO2, HK2, HLF, and 293A
Concentration:	0.1, 1, 5, and 10 µM
Incubation Time:	48 h and 72 h
Result:	Showed hypotoxicity with IC₅₀ values of 7.247, 4.586, 3.787, and 2.925 µM against LO2, HK2, HLF, and 293A cells, respectively. The cell morphology was changed compared to the control.

In Vivo

EGFR-IN-44 (Compound 6a) (25 mg/kg; i.g.; daily, 7days) shows strong antitumor activity without obvious toxicity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male BALB/c nude mice (5 weeks old, 18 - 20 g), H1975 xenograft model^[1]
Dosage:	25 mg/kg
Administration:	Intragastric administration, daily, 7 days
Result:	Showed strong tumor inhibition (TGI = 90.24%) without obvious toxicity.

Animal Model:

Male Sprague–Dawley (SD) rats^[1]

Dosage:

1 mg/kg and 5 mg/kg

Administration:

Intravenous injection and oral administration (Pharmacokinetic Analysis)

Result:

In Vivo PK parameters of EGFR-IN-44 ^[1]

Parameters Dose(mg/kg)	EGFR-IN-44 5 (po)	1 (iv)
t_1/2 (h)	8.60 ± 1.8	1.42 ± 0.1
T_max (h)	4.00 ± 0.002	/
C_max (ng/mL)	80.40 ± 2.7	/
Vz _{F_pred} (L/kg)	220.80 ± 41.2	6.83 ± 08
AUC_0-t (H.ng/mL)	490.41 ± 29.9	291.91 ± 38.2
AUC_0-∞ (H.ng/mL)	491.02 ± 44.2	295.76 ± 38.8
MRT_0-last (h)	7.93 ± 0.8	1.35 ± 01
CL (mL/h/kg)	17.79 ± 3.9	3.12 ± 0.4
F(%)	33.57 ± 5.9	/

F = (AUC_0-inf-PO × DOSE_IV)/(AUC_0-inf-IV × DOSE _PO)*100%.

Molecular Weight

537.08

Formula

C₂₇H₂₉ClN₆O₂S

SMILES

C=CC(NC1=CC(NC2=NC(C3=CSC4=CC=CC=C43)=C(C=N2)Cl)=C(C=C1N(CCN(C)C)C)OC)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Baijiao An, et al. Novel third-generation pyrimidines-based EGFR tyrosine kinase inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. Bioorg Chem. 2022 May;122:105743. [Content Brief]

EGFR-IN-44 Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

EGFR-IN-44EGFRApoptosisEpidermal growth factor receptorErbB-1HER1H1975AKTBcl-2BaxBadBALB/c nude micenon-small-cell lung cancers NSCLCInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks